Microbion’s Pravibismane Granted Second FDA Orphan Drug Designation for the Treatment of Non-tuberculous Mycobacterial (NTM) Infections

January 30, 2024•1 min read

Microbion recently announced another significant milestone in the development of its lead drug candidate, pravibismane. The U.S. FDA has granted pravibismane a second orphan drug designation for the treatment of non-tuberculous mycobacterial (NTM) infections.

Montana BioScience Alliance

Montana BioScience Alliance is the statewide organization dedicated to advancing and advocating for Montana’s bioscience industry. The Alliance connects researchers, companies, and policymakers to strengthen research, support responsible policy, and drive economic growth across the state.

Back to Blog